bmy 7378 has been researched along with Cardiomegaly in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andrade-Jorge, E; Estrada-Soto, SE; Gallardo-Ortíz, IA; Jiménez-Flores, JR; Martínez-Aguilar, L; Ramírez-Hernández, D; Rodríguez, JE; Saucedo-Campos, AD; Touyz, RM; Vega, AV; Villalobos-Molina, R | 1 |
| Katus, HA; Kemken, D; Kurz, T; Mier, K; Richardt, G | 1 |
2 other study(ies) available for bmy 7378 and Cardiomegaly
| Article | Year |
|---|---|
The α1D-adrenoreceptor antagonist BMY 7378 reverses cardiac hypertrophy in spontaneously hypertensive rats.
Topics: Adrenergic alpha-Antagonists; Animals; Blood Pressure; Cardiomegaly; Heart; Piperazines; Rats; Rats, Inbred WKY | 2020 |
Adrenergic activation of cardiac phospholipase D: role of alpha(1)-adrenoceptor subtypes.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Cardiomegaly; Clonidine; Dioxanes; Male; Myocardium; Norepinephrine; Perfusion; Phospholipase D; Piperazines; Prazosin; Propranolol; Rats; Rats, Wistar; Receptors, Adrenergic, alpha-1; Signal Transduction; Stimulation, Chemical | 2002 |